Improvement of specific immunotherapy by human IgG and modified allergens

Poulsen, Lars K.; Søundergaard, I.; Weeke, B.

doi:10.1111/j.1398-9995.1989.tb01065.x

Cited by 5 publications

(4 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The idea of creating low‐allergenic molecules has a long history in allergy (historical studies reviewed in 427 ) being inspired by the vaccinology field that has a century‐long tradition of creation of toxoids, i.e., modified bacterial toxins, which could be used for vaccination to raise a protective immune response but without the serious pathogenic effects of the native toxins. The allergenic counterpart, sometimes referred to as allergoids or more commonly as hypoallergens, is an allergen‐related molecule that has the capability to raise an immune response, preferably both in the B‐ (IgG) and T‐cell compartment of the immune system but without the elicitation of the well‐known allergic effects when administered to the allergic patient.…”

Section: A09 – Immunotherapy and Molecular Allergy Approachesmentioning

confidence: 99%

“…The idea of creating low-allergenic molecules has a long history in allergy (historical studies reviewed in 427 ) being inspired by the vaccinology field that has a century-long tradition of creation of toxoids, i.e., modified bacterial toxins, which could be used for vaccination to raise a protective immune response but without the serious pathogenic effects of the native toxins. The allergenic coun- In a large EU-funded project of collaborating academical, clinical and commercial groups it was attempted to develop hypoallergenic versions of the molecules Pru p 3 from peach 428 and Cyp c 1 from carp.…”

Section: B Hypoallergensmentioning

confidence: 99%

See 1 more Smart Citation

EAACIMolecular Allergology User's Guide 2.0

Dramburg

Hilger

Santos

et al. 2023

Pediatric Allergy Immunology

102

View full text Add to dashboard Cite

Since the discovery of immunoglobulin E (IgE) as a mediator of allergic diseases in 1967, our knowledge about the immunological mechanisms of IgE‐mediated allergies has remarkably increased. In addition to understanding the immune response and clinical symptoms, allergy diagnosis and management depend strongly on the precise identification of the elicitors of the IgE‐mediated allergic reaction. In the past four decades, innovations in bioscience and technology have facilitated the identification and production of well‐defined, highly pure molecules for component‐resolved diagnosis (CRD), allowing a personalized diagnosis and management of the allergic disease for individual patients. The first edition of the “EAACI Molecular Allergology User's Guide” (MAUG) in 2016 rapidly became a key reference for clinicians, scientists, and interested readers with a background in allergology, immunology, biology, and medicine. Nevertheless, the field of molecular allergology is moving fast, and after 6 years, a new EAACI Taskforce was established to provide an updated document. The Molecular Allergology User's Guide 2.0 summarizes state‐of‐the‐art information on allergen molecules, their clinical relevance, and their application in diagnostic algorithms for clinical practice. It is designed for both, clinicians and scientists, guiding health care professionals through the overwhelming list of different allergen molecules available for testing. Further, it provides diagnostic algorithms on the clinical relevance of allergenic molecules and gives an overview of their biology, the basic mechanisms of test formats, and the application of tests to measure allergen exposure.

show abstract

Section: A09 – Immunotherapy and Molecular Allergy Approachesmentioning

confidence: 99%

Section: B Hypoallergensmentioning

confidence: 99%

EAACIMolecular Allergology User's Guide 2.0

Dramburg

Hilger

Santos

et al. 2023

Pediatric Allergy Immunology

102

View full text Add to dashboard Cite

show abstract

“…Neither does immunotherapy appear to influence the IgE level. In this respect, the animal model resembles the human immunotherapy situation, in which the IgE level does not decrease substantially during or after therapy (7,22,25).…”

Section: Disgussion ' •'mentioning

confidence: 99%

“…Allergen-specific immunotherapy (IT) is a well-its effects are exerted (13,22). In our laboratory established formi of treatment given to patients we have focused on the IgG immune response with a clear diagnosis of asthma or rhinitis to produced during the first months of specific major inhalant allergens (13).…”

mentioning

confidence: 99%

Allergen‐containing immune complexes used for immunotherapy of allergic asthma

Lundberg

Søndergaard³

et al. 1991

Allergy

Self Cite

View full text Add to dashboard Cite

In a previous study guinea pigs inbred for their ability to develop respiratory anaphylaxis to experimental antigens have been used for comparison of different forms of immunotherapy (IT). Passive, active and combined (immune complexes prepared from antigen and specific IgG) IT was compared with placebo. In the present study methods were evaluated for determination of the allergen-specific IgE and IgG. IgE was determined by the passive cutaneous anaphylactic test (PCA) and the variability of this test on different strains of the recipient guinea pig was investigated. The same strain as used for the IT study was found to produce the most potent response. Radioimmunometric assays (RIA) were developed and validated for determination of specific IgG1 and IgG2. The IgE and IgG immune response in animals from the IT study were then evaluated by means of PCA and RIA. Animals from all four treatment groups were sensitized during the first part of the IT study, and responded with a marked IgE synthesis which later stabilized on a more moderate level. In spite of notably reduced symptoms in groups treated with active and combined IT, no difference in the IgE level was found between the four groups. In contrast to IgE, mean group titers of IgG1 and IgG2 in the groups receiving active or combined IT rose drastically during the first part of therapy and closely paralleled the clinical response during the rest of the study period. However, in the individual animals, no correlations were found between immune response and clinical symptoms. Thus, the strong IgG response during immunotherapy may not be causally related to the outcome of treatment.

show abstract